Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
INTENSITY THERAPEUTICS INC (INTS)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$3.10-11.43%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for INTS yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Sufficient capital to fund operations and R&D | The firm is raising capital to support development and growth. | Intact | ATM capacity falls below $30 million or inability to raise funds | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is speculative clinical-stage growth, not an established earnings compounder, and current evidence shows the company is loss-making with high risk. The long-term thesis is in a watch state: key studies are progressing, but financial performance has lagged its industry cohort.
The evidence does not provide a valuation comparison or specific market expectations, so it is not possible to say whether the shares look cheap, fair, or expensive versus peers. Recent earnings misses and a high near-term miss risk point to a cautious expectations backdrop, but the extent of what is already priced in is unclear.
Near term, earnings risk is elevated: INTS has missed in two of its three listed recent reports, and the evidence flags a high chance of another miss. Over the multi-year view, management has restarted treatment in the Phase 2 study and is working to resume Phase 3 enrollment, but cash fell in the latest quarter and the stated runway extends only to the end of Q1 2027.
The thesis hinges on continued enrollment and useful clinical evidence from the INVINCIBLE studies, alongside funding that sustains development. A guidance cut or further weakening in jobs data would add pressure, while continued strength from healthcare sector bellwethers could support the sector backdrop.
For the next 1 to 3 years, INTS is a high-risk, funding-dependent clinical story with encouraging early study signals but limited financial cushion and uneven results. The evidence supports a cautious long-term thesis, with confidence low. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Recent analyst EPS revisions show slight improvement from -0.84 to -0.73 next quarter. |
| Broken |
| EPS remains below -0.73 next quarter |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Advancement of drug delivery pipeline in immuno-oncology | The company has a strong research pipeline targeting immuno-oncology therapies. | Improving | Failure to achieve key clinical or regulatory milestones within 12 months | Qualitative: INVINCIBLE-4 enrollment targeted for end-2027; $30M raise for INVINCIBLE-3 News confirms INVINCIBLE-4 enrollment target for end-2027 and $30M capital raise for INVINCIBLE-3, indicating continued clinical progress. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-2.70 → $-2.25 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-2.70 | $0 | 2 / 2 |
| 2026-07-25 | $-3.40 | $351,000 | 1 / 2 |
| 2026-07-26 | $-2.70 | $0 | 2 / 2 |
| 2026-07-27 | $-3.40 | $351,000 | 1 / 2 |
| 2026-07-28 | $-3.40 | $351,000 | 1 / 2 |
| 2026-07-29 | $-2.70 | $0 | 2 / 2 |
| 2026-07-30 | $-2.70 | $0 | 2 / 2 |
| 2026-07-31 | $-2.70 | $0 | 2 / 2 |
| 2026-08-01 | $-3.40 | $351,000 | 1 / 2 |
| 2026-08-02 | $-2.70 | $0 | 2 / 2 |
| 2026-08-03 | $-2.70 | $0 | 2 / 2 |
| 2026-08-04 | $-2.70 | $0 | 2 / 2 |
| 2026-08-05 | $-2.70 | $0 | 2 / 2 |
| 2026-08-06 | $-2.70 | $0 | 2 / 2 |
| 2026-08-07 | $-3.40 | $351,000 | 1 / 2 |
| 2026-08-08 | $-2.70 | $0 | 2 / 2 |
| 2026-08-09 | $-2.70 | $0 | 2 / 2 |
| 2026-08-10 | $-2.70 | $0 | 2 / 2 |
| 2026-08-12 | $-3.40 | $351,000 | 1 / 2 |
| 2026-08-13 | $-3.40 | $351,000 | 1 / 2 |
| 2026-08-14 | $-3.40 | $351,000 | 1 / 2 |
| 2026-08-15 | $-3.40 | $351,000 | 1 / 2 |
| 2026-08-16 | $-3.40 | $351,000 | 1 / 2 |
| 2026-08-17 | $-3.40 | $351,000 | 1 / 2 |
| 2026-08-18 | $-3.40 | $351,000 | 1 / 2 |
| 2026-08-19 | $-3.40 | $351,000 | 1 / 2 |
| 2026-08-20 | $-2.25 | $351,000 | 2 / 3 |
| 2026-08-21 | $-2.25 | $351,000 | 2 / 3 |
| 2026-08-22 | $-2.25 | $351,000 | 2 / 3 |
| 2026-08-23 | $-2.25 | $351,000 | 2 / 3 |
| 2026-08-24 | $-2.25 | $351,000 | 2 / 3 |
| 2026-08-25 | $-2.25 | $351,000 | 2 / 3 |
| 2026-08-26 | $-2.25 | $351,000 | 2 / 3 |
| 2026-08-27 | $-2.25 | $351,000 | 2 / 3 |
| 2026-08-28 | $-2.25 | $351,000 | 2 / 3 |
| 2026-08-29 | $-2.25 | $351,000 | 2 / 3 |
| 2026-08-30 | $-2.25 | $351,000 | 2 / 3 |
| 2026-08-31 | $-2.25 | $351,000 | 2 / 3 |
| 2026-09-01 | $-2.25 | $351,000 | 2 / 3 |
| 2026-09-02 | $-2.25 | $351,000 | 2 / 3 |
| 2026-09-03 | $-2.25 | $351,000 | 2 / 3 |
| 2026-09-04 | $-2.25 | $351,000 | 2 / 3 |
| 2026-09-05 | $-2.25 | $351,000 | 2 / 3 |
| 2026-09-06 | $-2.25 | $351,000 | 2 / 3 |
| 2026-09-07 | $-2.25 | $351,000 | 2 / 3 |
| 2026-09-08 | $-2.25 | $351,000 | 2 / 3 |
| 2026-09-09 | $-2.25 | $351,000 | 2 / 3 |
| 2026-09-10 | $-2.25 | $351,000 | 2 / 3 |
| 2026-09-11 | $-2.25 | $351,000 | 2 / 3 |
| 2026-09-12 | $-2.25 | $351,000 | 2 / 3 |
| 2026-09-13 | $-2.25 | $351,000 | 2 / 3 |
| 2026-09-14 | $-2.25 | $351,000 | 2 / 3 |
| 2026-09-15 | $-2.25 | $351,000 | 2 / 3 |
| 2026-09-16 | $-2.25 | $351,000 | 2 / 3 |
| 2026-09-17 | $-2.25 | $351,000 | 2 / 3 |
| 2026-09-18 | $-2.25 | $351,000 | 2 / 3 |
| 2026-09-19 | $-2.25 | $351,000 | 2 / 3 |
| 2026-09-20 | $-2.25 | $351,000 | 2 / 3 |
| 2026-09-21 | $-2.25 | $351,000 | 2 / 3 |
| 2026-09-22 | $-2.25 | $351,000 | 2 / 3 |
| 2026-09-23 | $-2.25 | $351,000 | 2 / 3 |
| 2026-09-24 | $-2.25 | $351,000 | 2 / 3 |
| 2026-09-25 | $-2.25 | $351,000 | 2 / 3 |
| 2026-09-26 | $-2.25 | $351,000 | 2 / 3 |
| 2026-09-27 | $-2.25 | $351,000 | 2 / 3 |
| 2026-09-28 | $-2.25 | $351,000 | 2 / 3 |
| 2026-09-29 | $-2.25 | $351,000 | 2 / 3 |
| 2026-09-30 | $-2.25 | $351,000 | 2 / 3 |
| 2026-10-01 | $-2.25 | $351,000 | 2 / 3 |
| 2026-10-02 | $-2.25 | $351,000 | 2 / 3 |
| 2026-10-03 | $-2.25 | $351,000 | 2 / 3 |
| 2026-10-04 | $-2.25 | $351,000 | 2 / 3 |
| 2026-10-05 | $-2.25 | $351,000 | 2 / 3 |
| 2026-10-06 | $-2.25 | $351,000 | 2 / 3 |
| 2026-10-07 | $-2.25 | $351,000 | 2 / 3 |
| 2026-10-08 | $-2.25 | $351,000 | 2 / 3 |
| 2026-10-09 | $-2.25 | $351,000 | 2 / 3 |
| 2026-10-10 | $-2.25 | $351,000 | 2 / 3 |
| 2026-10-11 | $-2.25 | $351,000 | 2 / 3 |
| 2026-10-12 | $-2.25 | $351,000 | 2 / 3 |
| 2026-10-13 | $-2.25 | $351,000 | 2 / 3 |
| 2026-10-14 | $-2.25 | $351,000 | 2 / 3 |
| 2026-10-15 | $-2.25 | $351,000 | 2 / 3 |
| 2026-10-16 | $-2.25 | $351,000 | 2 / 3 |
| 2026-10-17 | $-2.25 | $351,000 | 2 / 3 |
| 2026-10-18 | $-2.25 | $351,000 | 2 / 3 |
| 2026-10-19 | $-2.25 | $351,000 | 2 / 3 |
| 2026-10-20 | $-2.25 | $351,000 | 2 / 3 |
| 2026-10-21 | $-2.25 | $351,000 | 2 / 3 |
| 2026-10-22 | $-2.25 | $351,000 | 2 / 3 |
| 2026-10-23 | $-2.25 | $351,000 | 2 / 3 |
| 2026-10-24 | $-2.25 | $351,000 | 2 / 3 |
| 2026-10-25 | $-2.25 | $351,000 | 2 / 3 |
| 2026-10-26 | $-2.25 | $351,000 | 2 / 3 |
| 2026-10-27 | $-2.25 | $351,000 | 2 / 3 |
| 2026-10-28 | $-2.25 | $351,000 | 2 / 3 |
| 2026-10-29 | $-2.25 | $351,000 | 2 / 3 |
| 2026-10-30 | $-2.25 | $351,000 | 2 / 3 |
| 2026-10-31 | $-2.25 | $351,000 | 2 / 3 |
| 2026-11-01 | $-2.25 | $351,000 | 2 / 3 |
| 2026-11-02 | $-2.25 | $351,000 | 2 / 3 |
| 2026-11-03 | $-2.25 | $351,000 | 2 / 3 |
| 2026-11-04 | $-2.25 | $351,000 | 2 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 6 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.